StockNews.com Lowers Chimerix (NASDAQ:CMRX) to Sell

StockNews.com lowered shares of Chimerix (NASDAQ:CMRX) from a hold rating to a sell rating in a research note released on Friday morning.

Several other research firms have also commented on CMRX. HC Wainwright reaffirmed a buy rating and set a $11.00 price target on shares of Chimerix in a research report on Friday, March 1st. Wedbush reaffirmed an outperform rating and set a $6.00 target price on shares of Chimerix in a report on Monday, February 12th.

Chimerix Stock Up 0.3 %

Shares of Chimerix stock opened at $0.95 on Friday. Chimerix has a twelve month low of $0.88 and a twelve month high of $1.57. The company has a market cap of $85.41 million, a price-to-earnings ratio of -1.02 and a beta of 1.13. The company’s 50 day moving average is $1.04 and its 200 day moving average is $1.00.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 39.62%. During the same period in the prior year, the firm earned ($0.24) EPS. Sell-side analysts expect that Chimerix will post -0.81 EPS for the current fiscal year.

Institutional Trading of Chimerix

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in Chimerix by 190.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 387,638 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of Chimerix by 167.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 426,672 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 267,044 shares during the period. Pale Fire Capital SE bought a new stake in shares of Chimerix during the 3rd quarter valued at $95,000. RA Capital Management L.P. purchased a new position in shares of Chimerix during the 3rd quarter valued at $6,240,000. Finally, Vance Wealth Inc. bought a new position in Chimerix in the 4th quarter worth $46,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.